Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial by Katsambas, Andreas et al.
ORIGINAL ARTICLEadi2_23 66..70
Assessing the Impact of Efalizumab on Nail, Scalp and
Palmoplantar Psoriasis and on Quality of Life: Results from a
Multicentre, Open-label, Phase IIIb/IV Trial
Andreas Katsambas,* Ketty Peris,
† Gino Vena,
‡ Peter Freidmann,
§ Gottfried Wozel,
¶
Esteban Daudén,** Daiana Licu,
†† Mauro Placchi,
†† and Michel De La Brassinne
‡‡
*Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece;
†University of L’Aquila,
Aquila, Italy;
‡Dermatology Clinic, University of Bari, Bari, Italy;
§Southampton General Hospital, Southampton, UK;
¶Department of Dermatology, Technical University, Dresden, Germany; **Hospital Universitario de la Princesa, Madrid,
Spain;
††Merck Serono International S.A., Geneva, Switzerland;
‡‡Department of Dermatology, Centre Hospitalier
Universitaire, Liège, Belgium
DOI: 10.1111/j.1753-5174.2009.00023.x
ABSTRACT
This post-approval, open-label trial (n = 1266) assessed the efﬁcacy of efalizumab, administered in accordance with
the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received
subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By Week 12, an improvement from baseline of 50%
or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp
psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis. Quality of life improved throughout the trial,
with a 50% median improvement in DLQI score after 12 weeks of treatment. Efalizumab showed promising efﬁcacy
in the treatment of nail, scalp and palmoplantar psoriasis, which was reﬂected in improvements in quality of life.
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Introduction
P
soriasis frequently affects the nails, scalp,
palms of the hands and soles of the feet,
which can have disabling consequences and a
considerable negative impact on a patient’s
quality of life (QoL) [1–6]. It can be very difﬁcult
to treat; in particular, the nails and scalp are not
amenable to many topical psoriasis treatments or
phototherapy because the nail plate or hair,
respectively, prevent adequate contact with the
affected tissue [2,5–7].
Efalizumab is a recombinant monoclonal
immunoglobulin G1 antibody that binds to the
CD11a subunit of lymphocyte function-associated
antigen type 1. Until early 2009 it was approved in
Europe for the treatment of adults suffering from
moderate-to-severe chronic plaque psoriasis. This
study reports data from a large-scale, prospective
post-approval trial, the ﬁrst of its kind in psoriasis
patients, which assessed the efﬁcacy and safety of
efalizumab therapy in patients treated according
to the European label at that time. Separately
reported ﬁndings from this trial indicated that
efalizumab effectively controlled psoriasis in two-
thirds of patients within 12 weeks, and that this
was maintained in over three-quarters of patients
who continued to receive treatment for a total of
20 weeks [8]. In this article we present results from
this trial for patient subgroups presenting with
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QoL outcomes for the entire patient population.
Methods
Patients
The trial included patients aged 18 years with a
diagnosis of moderate-to-severe plaque psoriasis
who had failed to respond to, were contraindicated
for, or were intolerant of other systemic therapies,
including ciclosporin, methotrexate and psoralen
plus ultraviolet (UV)A phototherapy. Key exclu-
sion criteria included guttate, erythrodermic or
pustular psoriasis as the sole or predominant form
of psoriasis; withdrawal from previous efalizumab
treatment as a result of lack of efﬁcacy or an
adverse event; history of opportunistic infections
or ongoing uncontrolled infections or active
tuberculosis (TB), or treatment for TB within 1
year prior to entry. Written informed consent was
obtained from all patients enrolled in the trial.
Trial Design
The trial design is described in detail elsewhere
[8]. Brieﬂy, after a single subcutaneous (s.c.)
conditioning dose of efalizumab 0.7 mg/kg, eli-
gible patients received open-label s.c. efalizumab
1.0 mg/kg once weekly for a further 11 weeks
(ﬁrst-treatment period). At Week 12, responders
could opt to continue with efalizumab treatment
for a further 8 weeks while nonresponders
switched to an alternative approved anti-psoriasis
medication for up to 12 weeks. Regardless of their
response, patients could choose to discontinue
anti-psoriasis medication at Week 12; these
patients entered the observation period and were
monitored without treatment for up to 8 weeks or
until signs of worsening psoriasis were observed.
Patients who responded during the ﬁrst-treatment
period but experienced worsening psoriasis during
the observation period could then receive further
treatment with weekly open-label s.c. efalizumab
1.0 mg/kg for a further 12 weeks. The trial was
performed in accordance with the Declaration of
Helsinki Guidelines for Good Clinical Practice,
with approval by the independent ethics
committee/institutional review board for each
participating country.
Assessments of Nail, Scalp and
Palmoplantar Psoriasis
Nail Psoriasis Severity Index (NAPSI) assessments
were made at baseline and at Week 12 of the trial.
Psoriasis Scalp Severity Index (PSSI) assessments
and Palmoplantar Pustulosis Psoriasis Area and
Severity Index (PPPASI) assessments were made at
baseline and at Weeks 4, 8 and 12. In each case,
higher scores indicate greater disease severity.
Assessment of Quality of Life
QoL was assessed at baseline and Weeks 2, 4, 8, 12
and 20 using the Dermatology Life Quality Index
(DLQI) and the Medical Outcomes Study Short
Form-36 (SF-36).
Statistical Considerations
The intent-to-treat (ITT) population included all
patients who received at least one dose of efali-
zumab and had at least one post-dose efﬁcacy
assessment.
Only subjects with baseline NAPSI, PSSI or
PPPASI scores greater than zero were included in
the nail, scalp or palmoplantar efﬁcacy analyses,
respectively. The proportions of patients achieving
an improvement from baseline of 50% (NAPSI
50; PSSI 50; PPPASI 50) and 75% (NAPSI
75; PSSI 75; PPPASI 75) at Week 12 were
determined.
Descriptive statistics were presented for SF-36
and DLQI data. For SF-36, a subscale score was
included for patients who responded to at least half
of the questions in that subscale; the mean score
was calculated from the available responses.
For categorical data analyses, patients missing
Week 12 data were considered to be non-
responders (worst-outcome imputation). For con-
tinuous data, patients with a missing value were
excluded from the analysis at the time point for
which the data were missing.
Results
Patients
Of the 1266 patients enrolled to the trial, 11 were
excluded due to lack of post-baseline efﬁcacy
assessment data. Thus the ITT population com-
prised 1255 patients (68.5% male; mean age 46.2
years). Of these, 1084 completed the ﬁrst 12 weeks
of treatment, with 171 patients withdrawing from
treatment for the following reasons: adverse event
(n = 81); lost to follow-up (n = 8); protocol viola-
tion (n = 3); lack of efﬁcacy (n = 52); other (n = 27).
A total of 688 patients, most of whom had
responded to treatment during the initial 12-week
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for a further 8 weeks, for a total of 20 weeks of
efalizumab therapy.
Efﬁcacy in Nail Psoriasis
There were 844 patients with a NAPSI score
greater than zero at baseline (Table 1). The
median improvement in NAPSI score from base-
line to Week 12 was 10% (interquartile range
[IQR] 0–42.9). By Week 12, 21.4% (181/844) of
patients achieved NAPSI 50, and 13.3% (112/844)
achieved NAPSI 75 (Figure 1).
Efﬁcacy in Scalp Psoriasis
A PSSI score greater than zero was recorded for
1150 patients at baseline (Table 1). By Week 12,
there had been a median improvement in PSSI
score of 73.3% (IQR 33.3–94.3) compared with
baseline.
At Week 12, PSSI 50 and PSSI 75 responses
were achieved by 62.4% (718/1150) and 44.7%
(514/1150) of patients, respectively (Figure 1).
In many cases, a response to efalizumab was
apparent early in treatment (Table 2), with over
half of the patients classiﬁed as PSSI 50 responders
at Week 12 having already achieved this response
by Week 4 (n = 425).
Efﬁcacy in Palmoplantar Psoriasis
There were 247 patients with a PPPASI score
greater than zero at baseline (Table 1).
At Week 12, the median improvement in
PPPASI score from baseline was 69.4% (IQR 0.0–
100.0), with 51.4% (127/247) of patients achieving
PPPASI 50 response, and 42.5% (105/247) of
patients achieving PPPASI 75 response (Figure 1).
Quality of Life
Dermatology Life Quality Index
A total of 1192 patients from the ITT population
had DLQI data at baseline while 1044 patients had
DLQI data at Week 12. DLQI scores ranged from
0 to 30 at baseline, with a median of 10 (IQR
5.0–16.0). Median DLQI scores improved steadily
from baseline to Week 12 (Figure 2a). Among
patients from the ITT population who had DLQI
data at Week 12, the median improvement from
baseline was 5 points (IQR 1.0–10.0).
A total of 601 patients from the ITT population
continued efalizumab treatment beyond Week 12
with recorded DLQI data at Week 20. The
median DLQI score for this subset of patients at
Week 20 was 2.0 (IQR 0.0–6.0; range 0.0–30.0)
Table 1 Nail and Psoriasis Severity Index (NAPSI), Psoriasis Scalp Severity Index (PSSI) and Palmoplantar Pustulosis
Psoriasis Area and Severity Index (PPPASI) scores at baseline and Week 12
NAPSI PSSI PPPASI
Number of patients with score >0 at baseline 844 1150 247
Number (%) of patients with high score at baseline 353 (41.8)* 408 (35.5)
† 109 (44.1)
‡
Median score (range)
At baseline 24.0 (1–80) 16.0 (1–72) 4.0 (0.2–43.2)
At Week 12 20.0 (0–80) 3.0 (0–60) 1.20 (0.0–53.0)
*Score 29; †score >21; ‡score 5.
Figure 1 Proportions of patients achieving a 50% or 75%
improvement from baseline to Week 12 in Nail Psoriasis
Severity Index (NAPSI), Psoriasis Scalp Severity Index
(PSSI), or Palmoplantar Pustulosis Psoriasis Area and
Severity Index (PPPASI) score; intent-to-treat populations.
Table 2 Median Psoriasis Scalp Severity Index (PSSI)
and Palmoplantar Pustulosis Psoriasis Area and Severity
Index (PPPASI) scores (interquartile range) by visit
PSSI PPPASI
Baseline 16.0 (6.0–28.0) 4.00 (1.20–11.20)
n = 1150 n = 247
Week 4 9.0 (3.0–18.0) 2.40 (0.60–6.70)
n = 1138 n = 242
Week 8 6.0 (2.0–12.0) 2.00 (0.20–5.60)
n = 1093 n = 229
Week 12 3.0 (1.0–10.0) 1.20 (0.00–4.80)
n = 1042 n = 216
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ment from baseline of 60% (6.0 points; IQR 2.0–
12.0).
Medical Outcomes Study Short Form-36
SF-36 scores ranged from 40.0 to 792.0 (median
571.5; IQR 419.0–665.3) at baseline and improved
steadily from baseline to Week 12. At Week 12,
986 patients from the ITT population had SF-36
data recorded. Among these patients, the median
SF-36 score at Week 12 was 645.0 (range 70.0–
800.0; IQR 503.0–708.0). This represents a mean
improvement from baseline of 58.3 points (stand-
ard deviation 144.5; IQR -10.8–129.4).
Among those patients who continued efali-
zumab treatment beyond Week 12 and had SF-36
data at Week 20 (n = 563), the median SF-36 score
was 658.5 (range 68.0–800.0; IQR 551.5–716.5) at
Week 20, which was a 9.4% improvement from
baseline.
Safety
Efalizumab was well tolerated. Full safety data are
reported in the primary trial publication [8].
Discussion
This report describes the results arising from the
secondary analysis of a large-scale prospective
post-approval trial examining the efﬁcacy and
safety of efalizumab in patients with moderate-to-
severe, chronic plaque psoriasis who had failed to
respond to, had contraindications for, or were
intolerant of other systemic therapies, including
ciclosporin, methotrexate and psoralen plus UVA
phototherapy. Evaluation of the primary end-
points of this trial have shown the safety and efﬁ-
cacy of efalizumab across the patient population as
a whole [8].
A subgroup analysis of patients presenting with
nail, scalp or palmoplantar psoriasis within this
same trial are described herein. The data pre-
sented indicate that treatment with efalizumab for
12 weeks also resulted in a marked improvement in
these conditions. In patients with scalp or pal-
moplantar involvement, over 40% of patients
achieved at least a 75% improvement in symptoms
by Week 12. Similarly, of the patients with nail
involvement, more than one-ﬁfth achieved at least
a 50% improvement in symptoms by Week 12.
These results support and extend the favourable
ﬁndings of earlier smaller-scale trials reported in
the Latin American CONTROL I trial [9] or the
placebo-controlled Phase IV hand and foot plaque
psoriasis trial [10].
Psoriasis can greatly inﬂuence a patient’s self-
esteem and sense of well-being, and consequently
is detrimental to their QoL. The beneﬁcial effects
Figure 2 Median (interquartile range) Dermatology Life Quality Index score (a) Weeks 0–12, intent-to-treat population;
(b) Week 20, continuous-treatment population.
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were paralleled by steady improvements in QoL
throughout the initial 12-week efalizumab treat-
ment period. This trend, along with the 50%
(5-point) improvement in DLQI score from base-
line to Week 12 of efalizumab treatment, is also in
accordance with the results of previous studies
examining QoL following treatment in psoriasis
patients [11–15].
In light of post-marketing surveillance of
patients with psoriasis receiving efalizumab con-
tinuously for more than 3 years, in which oppor-
tunistic infections were reported, and in particular
cases of JC virus infection resulting in progressive
multifocal leucoencephalopathy (PML), the Euro-
pean Medicines Agency evaluated all safety data. It
concluded that the beneﬁts of efalizumab treat-
ment no longer outweighed the risks associated
with the drug and recommended suspension of
marketing authorization on 19 February 2009.
This trial has conﬁrmed that efalizumab,
administered in accordance with the European
label available at that time, provided effective
control of moderate-to-severe plaque psoriasis.
This latest analysis indicates that efalizumab can
also be an effective treatment in difﬁcult-to-treat
forms of the disease, including nail, scalp or pal-
moplantar psoriasis, with profound effects on a
patient’s QoL.
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